Wockhardt NCE, WCK 4873 named as Nafithromycin was comparatively evaluated in multi centre double blind phase 3 pneumonia study employing the last-line respiratory antibiotic Moxifloxacin.
The results of the study showed that an ultrashort course of 3 day treatment with Nafithromycin is as effective as 7 day therapy with Moxifloxacin. The findings of Phase 3 study are in line with phase 2 study conducted in the US and Europe, said the company.
A human lung penetration study conducted in the US revealed that Nafithromycin possesses a remarkable feature of sustained high lung concentration built up over 5 days following just 3 days of dosing. Human Lung exposure of Nafithromycin is 8 times higher than Azithromycin and potency being 10-100 times higher for certain respiratory pathogens.
In phase 3 study, three-day treatment with Nafithromycin resulted in clinical cure for 96.7% of patients as against clinical cure rate of 94.5 % in Moxifloxacin arm. The phase 3 study outcome establishes broadspectrum efficacy of Nafithromycin against gram-positive respiratory pathogens, fastidious Gramnegative pathogens as well as therapeutically challenging intracellular atypical pathogens such as Mycoplasma pneumoniae, which were recently implicated for the surge of hospitalisations in China due to pneumonia. A significant proportion of study patients were infected with pathogens showing resistance to Azithromycin, Amoxycillin+clavulanic acid and Levofloxacin.
The phase 3 study did not encounter any serious adverse event (AE), all the reported AEs were mild, and most were considered unrelated to the study drugs by the investigators except for nausea and gastrointestinal effects.
The study also establishes that Nafithromycin represents a first ever macrolide in 30 years which has successfully completed clinical development for the indication of community acquired bacterial pneumonia.
Recent Indian Council of Medical Research (ICMR) surveillance data shows 65% resistance to Erythromycin in Indian pneumococcal isolates and globally up to 40% resists to Azithromycin. China has alarmingly high incidence of over 80% resistance to azithromycin among pneumococci.
As per the infectious disease related mortality burden reported in the December 2022 issue of the Lancet, estimated deaths in India due to pneumococcal infection amounted to 151,768. In conclusion, Nafithromycin is a major advancement in 30 years for treatment of pneumonia, which is effective and safe for community usage for resistant organisms.
Wockhardt is a global pharmaceutical and biotechnology company engaged into developing, manufacturing and marketing of finished dosage and biopharmaceutical formulations, active pharmaceutical ingredients (APIs) and vaccines.
The pharma company reported a consolidated net loss of Rs 73 crore in Q2 FY24 as compared with net loss of Rs 207 crore posted in Q2 FY23. Total revenue rose 11% year on year to Rs 762 crore in the second quarter of FY24.
The scrip hit 52-week high of Rs 398.95 in today’s intraday session.